



Atty. Docket No.: 8654/2002

PATENT

10.0
ver
5-18-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Eberhard Amtmann

Examiner: Goldberg, Jerome D.

Serial No.: 09/784,618

Filed: February 15, 2001

Group Art Unit: 1614

Entitled: "Medicament Containing Platinum Complex Compounds And The Use Thereof"

Conf. No.: 2652

TECH. CENTER 1600/2900

MAY 07 2002

RECEIVED

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that the paper (and any paper or fee referred to as being enclosed) is being deposited with the United States Postal Service using Express Mail to Addressee Service, under 37 C.F.R. Section 1.10, **Express Mail Label No. EV097554795US** on this date, **May 2, 2002**, postage prepaid, in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

David J. Dykeman

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

This paper is supplemental to our filing of February 15, 2001. Applicants believe that no fee is due with this filing; however, please charge any necessary fees required in connection with the paper transmitted herewith to Deposit Account No. 16-0085, Reference No. 8654/2002.

AMENDMENT

Please amend the above-identified application as follows:

IN THE SPECIFICATION

On page 5, in the second line of the third full paragraph, after "colonic" insert --carcinomas,-- so the third full paragraph on page 5 reads as follows:

D2 The compounds of formula (I) are suitable for treating various cancerous diseases, such as testicular tumors, ovarian carcinomas, bladder carcinomas, colonic carcinomas, prostatic carcinomas, parvocellular and non-parvocellular bronchial carcinomas, carcinomas of the cephalic and cervical parts, carcinomas of the thoracic and abdominal regions, cervical and endometrial carcinomas, sarcomas and melanomas as well as leukemias. The treatment of the parvocellular bronchial carcinoma or colorectal carcinoma is preferred. The treatment can also be carried out as a treatment associated with a radiotherapy or before and/or after an operation.

This Amendment to the specification is to correct translation errors, and no new matter is added.